重组人内皮抑素联合化疗在NSCLC中的疗效观察  

Clinical effect of endostatin combined with chemotherapy for advanced non-small cell lung cancer

作　　者：杨振华[1] 叶亮[1] 王文晶[1] 张静[1] 谷伟[1] 

机构地区：[1]南京医科大学附属南京医院呼吸科,江苏南京210006

出　　处：《临床肺科杂志》2015年第5期793-795,共3页Journal of Clinical Pulmonary Medicine

基　　金：江苏省卫生厅面上项目(No H201341)

摘　　要：目的探讨恩度联合化疗在NSCLC患者中的临床疗效及安全性。方法 46例单纯化疗组,32例重组内皮抑素联合化疗组。结果治疗2个周期后RR分别是19.6%、31.3%,DCR分别是87%、93.8%;治疗4个周期后RR分别是14.0%、23.3%,DCR分别是51.2%、80.0%(P<0.05);治疗6个周期后RR分别是10.5%、21.4%,DCR分别是47.7%、78.6%(P<0.05)。结论重组人内皮抑素可以明显提高晚期NSCLC患者的DCR,且具有较高的安全性。Objective To explore the clinical value and safety of endostatin combined with chemotherapy for NSCLC. Methods All patients were divided into two groups： 46 patients were treated with chemotherapy alone and32 patients were treated with endostatin plus chemotherapy. Results After two cycles＇ treatment,the value of RR and DCR was 19. 6% and 87% in the control group and 31. 3% and 93. 8% in the study group,respectively. After four cycles＇ treatment,the value of RR and DCR was 14% and 51. 2% in the control group and 23. 3% and 80% in the study group,respectively（ P〈 0.05）. After six cycles＇ treatment,the value of RR and DCR was 10. 5% and47. 7% in the control group and 21. 4% and 78. 6% in the study group,respectively（ P〈 0.05）. Conclusion Endostatin is safety and effective to improve the DCR after four and six cycles＇ treatment.

关 键 词：肺癌 血管内皮抑素 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]